Can I read Effectiveness of Antipsychotic Polypharmacy for Patients with Treatment Refractory Schizophrenia: an Open‐label Trial of Olanzapine Plus Risperidone for Those Who Failed to Respond to a Sequential Treatment with Olanzapine, Quetiapine and Risperidone on EtoBox?

Effectiveness of Antipsychotic Polypharmacy for Patients with Treatment Refractory Schizophrenia: an Open‐label Trial of Olanzapine Plus Risperidone for Those Who Failed to Respond to a Sequential Treatment with Olanzapine, Quetiapine and Risperidone by Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuke Nomura; Hiroyoshi Takeuchi; Akira Tanabe; Gohei Yagi; Haruo Kashima is a Medicine article available to read on EtoBox.

What is Effectiveness of Antipsychotic Polypharmacy for Patients with Treatment Refractory Schizophrenia: an Open‐label Trial of Olanzapine Plus Risperidone for Those Who Failed to Respond to a Sequential Treatment with Olanzapine, Quetiapine and Risperidone about?

## Abstract ## Objective To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner. ## Methods In this open‐label study, 17 patients with treatment‐refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and risperidone, were subsequently treated with a combination therapy with olanzapine plus risperidone for at least 8 weeks. ## Results Seven responded according to the primary endpoint defined as the post‐treatment Brief Psychiatric Rating Scale being less than 70% of the pretreatment values, and they were classified as such an average of 10 weeks after the initiation of polypharmacy. Two of them were successful in a later conversion to monotherapy. None dropped out prematurely. Four (out of 13 inpatients) got better enough to be discharged from the hospital, while six patients did not show any response. The Global Assessment of Functioning score improved from 37.1 to 53.0 in responders (mean maximum dose: olanzapine 12.9 mg; risperidone 3.14 mg), while it showed non‐significant changes among others (mean maximum dose: olanzapine 14.5 mg; risperidone 5.50 mg). Body weight, prolactin, and total cho

Who reads Effectiveness of Antipsychotic Polypharmacy for Patients with Treatment Refractory Schizophrenia: an Open‐label Trial of Olanzapine Plus Risperidone for Those Who Failed to Respond to a Sequential Treatment with Olanzapine, Quetiapine and Risperidone?

Author

Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuke Nomura; Hiroyoshi Takeuchi; Akira Tanabe; Gohei Yagi; Haruo Kashima

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0885-6222)

Published

2008

Language

EN

Field

Medicine (Health Sciences)